在各大洲实现羟基脲的有效性:撒哈拉以南非洲多中心REACH研究的入组与基线特征
REACH为前瞻性I/II期开放标签试验,评估羟基脲治疗撒哈拉以南非洲四国镰状细胞贫血儿童的可行性、安全性与获益。研究在30个月内入组635例参与者,入组前即达到完整入组目标;参与者年龄5.4±2.4岁,基线合并症负担重,各中心实验室特征存在差异。
要点
- REACH研究在30个月内入组635例镰状细胞贫血儿童,提前完成完整入组目标。
- 基线合并症包括血管闭塞性疼痛98%、输血68%、疟疾85%、卒中6%。
- 安哥拉和刚果民主共和国血红蛋白浓度低于肯尼亚和乌干达(P < .01)。
核心结论
- REACH研究的完整入组证实了在非洲开展高质量镰状细胞贫血研究的可行性。
- 该研究将为指导非洲镰状细胞贫血儿童安全有效的羟基脲给药提供重要信息。
研究设计与样本
- REACH(ClinicalTrials.gov NCT01966731)为前瞻性I/II期开放标签试验,评估羟基脲治疗撒哈拉以南非洲四国镰状细胞贫血儿童的可行性、安全性与获益。
- 研究在30个月期间入组635例参与者,半数家庭住所距临床中心超过12 km。
- 研究经当地伦理委员会批准,并对当地研究团队进行了全面培训。
主要发现
- 入组时参与者年龄5.4±2.4岁,有血管闭塞性疼痛史者98%、输血史者68%、疟疾史者85%、卒中史者6%。
- 安哥拉血红蛋白浓度7.2±1.0 g/dL、刚果民主共和国7.0±0.9 g/dL,低于肯尼亚7.4±1.1 g/dL和乌干达7.5±1.1 g/dL(P < .01)。
- 至少携带一个α珠蛋白基因缺失者占58.4%;G6PD缺乏在男性中占19.7%、女性中占2.4%;CAR β珠蛋白单倍型存在于99%的参与者中。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite its well-described safety and efficacy in the treatment of sickle cell anemia (SCA) in high-income settings, hydroxyurea remains largely unavailable in sub-Saharan Africa, where more than 75% of annual SCA births occur and many comorbidities exist. Realizing Effectiveness Across Continents with Hydroxyurea (REACH, ClinicalTrials.gov NCT01966731) is a prospective, Phase I/II open-label trial of hydroxyurea designed to evaluate the feasibility, safety, and benefits of hydroxyurea treatment for children with SCA in four sub-Saharan African countries. Following comprehensive training of local research teams, REACH was approved by local Ethics Committees and achieved full enrollment ahead of projections with 635 participants enrolled over a 30-month period, despite half of families living >12 km from their clinical site. At enrollment, study participants (age 5.4 ± 2.4 years) had substantial morbidity, including a history of vaso-occlusive pain (98%), transfusion (68%), malaria (85%), and stroke (6%). Significant differences in laboratory characteristics were noted across sites, with lower hemoglobin concentrations (P < .01) in Angola (7.2 ± 1.0 g/dL) and the DRC (7.0 ± 0.9 g/dL) compared to Kenya (7.4 ± 1.1 g/dL) and Uganda (7.5 ± 1.1 g/dL). Analysis of known genetic modifiers of SCA demonstrated a high frequency of α-thalassemia (58.4% with at least a single α-globin gene deletion) and G6PD deficiency (19.7% of males and 2.4% of females) across sites. The CAR β-globin haplotype was present in 99% of participants. The full enrollment to REACH confirms the feasibility of conducting high-quality SCA research in Africa; this study will provide vital information to guide safe and effective dosing of hydroxyurea for children with SCA living in Africa.
引用
- McGann PT, Williams TN, Olupot-Olupot P, et al. Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Sub-Saharan Africa. Am J Hematol. 2018. PMID: 29318647. doi:10.1002/ajh.25034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。